BMO Capital analyst Gary Nachman maintained a Buy rating on 9 Meters Biopharma (NMTR - Research Report) today and set a price target of $3.00. The company's shares opened today at $0.23.Nachman covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Horizon Therapeutics, and Ionis Pharmaceuticals. According to TipRanks, Nachman has an average return of -9.8% and a 37.58% success rate on recommended stocks. Currently, the analyst consensus on 9 Meters Biopharma is a Strong Buy with an average price target of $3.67.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $1.43 and a one-year low of $0.20.
https://www.tipranks.com/news/blurbs/9-meters-biopharma-nmtr-receives-a-buy-from-bmo-capital-4?utm_source=advfn.com&utm_medium=referral
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more 9 Meters Biopharma Charts.
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more 9 Meters Biopharma Charts.